LB-80380 maleate salt
| Code | Size | Price |
|---|
| TAR-T32611-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32611-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32611-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
LB-80380 maleate salt, a novel phosphonate nucleoside, is for the potential treatment of HBV infection.
CAS:
1039623-01-2
Formula:
C26H38N5O11P
Molecular Weight:
627.588
Purity:
0.98
SMILES:
OC(=O)C=C/C(O)=O.CC(C)(C)C(=O)OCOP(COC1(Cn2cnc3cnc(N)nc23)CC1)OCOC(=O)C(C)(C)C
References
1. Papatheodoridis GV, Manolakopoulos S. Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection. Curr Opin Mol Ther. 2006 Aug;8(4):352-7. Review. PubMed PMID: 16955699.
2. Lampertico P. Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. Gut. 2014 Jun;63(6):869-70. doi: 10.1136/gutjnl-2013-305859. Epub 2013 Oct 25. PubMed PMID: 24162592.
3. Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Lai CL, Han KH. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol. 2015 Mar;62(3):526-32. doi: 10.1016/j.jhep.2014.10.026. Epub 2014 Oct 25. PubMed PMID: 25450709.
4. Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014 Jun;63(6):996-1004. doi: 10.1136/gutjnl-2013-305138. Epub 2013 Aug 26. PubMed PMID: 23979965.